Holen Sie sich die Stockscreener-App
170.00
0.00%
0.00
Handel nachbörslich:
170.00
Schlusskurs vom Vortag:
$170.00
Offen:
$167
24-Stunden-Volumen:
579.57K
Relative Volume:
0.50
Marktkapitalisierung:
$13.11B
Einnahmen:
$8.24B
Nettoeinkommen (Verlust:
$222.68M
KGV:
62.49
EPS:
2.7203
Netto-Cashflow:
$888.99M
1W Leistung:
+1.36%
1M Leistung:
+18.66%
6M Leistung:
-6.91%
1J Leistung:
+15.74%
1-Tages-Spanne:
$167.00
$172.40
1-Wochen-Bereich:
$162.83
$173.23
52-Wochen-Spanne:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Compare ICLR vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
170.00 | 13.11B | 8.24B | 222.68M | 888.99M | 2.7203 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2026-02-23 | Hochstufung | Jefferies | Hold → Buy |
| 2026-02-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-17 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | Herabstufung | Truist | Buy → Hold |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-09-09 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-03 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
ICON PLC : Leerink Partners Raises Target Pri - Moomoo
Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline - Yahoo Finance
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
ICON Plc (ICLR) Stock Analysis: A Healthcare Giant With 7.81% Potential Upside - DirectorsTalk Interviews
ETFs Investing in ICON Plc Stocks - TradingView
Icon reiterates 2026 guidance of $7.85B-$8.15B revenue and $10-$11 EPS amid 1.42x net book-to-bill - MSN
Prosight Management, LP's Icon PLC(ICLR) Holding History - GuruFocus
ICON plc shares drop after internal probe into accounting practices announced - Pluang
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm - StreetInsider
ICON plc (ICLR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
RBC Capital Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $185 - 富途牛牛
ICON Stock and the CRO Trends Shaping Its Next Growth Phase - The Globe and Mail
ICON plc highlights its position in global clinical research. The Nasdaq-listed group continues to b - Ad-hoc-news.de
ICON Public Limited Company (ICLR) Fell Due to Uncertainty Surrounding Reported Earnings - Yahoo Finance
ICON plc outlines its role in global clinical research as a Nasdaq-listed CRO - ad-hoc-news.de
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset? - TradingView
ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base - TradingView
Icon PLC | 3: Initial statement of beneficial ownership of securities- O'Neill Julie - Moomoo
ICON shares rise as earnings beat and CEO flags strong booking momentum - MSN
ICLRIcon Plc Options - Finviz
ICON plc. Shares trade on Nasdaq amid steady business backdrop. - AD HOC NEWS
Icon Q1 2026 Earnings Call Transcript - MarketBeat
ICON Plc Financial Disclosures & Filings - TradingView
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $207 - Moomoo
Truist Financial Upgrades Icon PLC(ICLR.US) to Buy Rating, Announces Target Price $207 - Moomoo
Truist Upgrades ICON to Buy From Hold, Raises Price Target to $207 From $159, Cites Stronger Bookings, Improving Margin Visibility - Moomoo
Truist upgrades ICON stock rating on strong business wins By Investing.com - Investing.com South Africa
Icon PLC Company Profile & Introduction - Moomoo
Icon PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Shs Actuals & Estimates (BMFBOVESPA:ICLR34) - TradingView
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Raises Target Price to $190 - Moomoo
ICLR Maintained by Mizuho -- Price Target Raised to $190 - GuruFocus
ICON (ICLR) Slides as Investors Stay Cautious Ahead of Delayed Results Tied to Accounting Review - Moomoo
Icon PLC (ICLR) Shares Surge 5.5% -- What GF Score of 87 Tells I - GuruFocus
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $187 to $197 - Moomoo
What Just Happened at ICON (ICLR) and Why Did Shares Soar - Kavout | AI
Meeting Sites Where They Are: A Connected, Intelligence-Powered Operating Model - Fierce Pharma
Accounting restatement, big impairments and AGM plans at ICON plc (NASDAQ: ICLR) - Stock Titan
Enterprise value to EBITDA forward of ICON plc – NASDAQ:ICLR - TradingView
ICON Plc Actuals & Estimates (NASDAQ:ICLR) - TradingView
Enterprise value to EBIT forward of ICON plc – NASDAQ:ICLR - TradingView
Enterprise value to revenue forward of ICON plc – NASDAQ:ICLR - TradingView
ICON Plc Actuals & Estimates (FWB:IJF) - TradingView
Price to book forward of ICON plc – NASDAQ:ICLR - TradingView
Price to sales forward of ICON plc – NASDAQ:ICLR - TradingView
Mizuho raises ICON stock price target to $190 on bookings strength - Investing.com UK
Mizuho raises ICON stock price target to $190 on bookings strength By Investing.com - Investing.com Australia
Price to earnings forward of ICON plc – NASDAQ:ICLR - TradingView
IJF Forecast — Price Target — Prediction for 2027 - TradingView
ICON PLC : BMO Raises Target Price to $187 Fr - Moomoo
ICLR Maintained by TD Cowen -- Price Target Raised to $197 - GuruFocus
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $160 to $197 - Moomoo
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):